Atea Pharmaceuticals Beneish M Score

AVIR -  USA Stock  

USD 24.78  0.33  1.31%

This module uses fundamental data of Atea Pharmaceuticals to approximate the value of its Beneish M Score. Atea Pharmaceuticals M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Please continue to Atea Pharmaceuticals Piotroski F Score and Atea Pharmaceuticals Altman Z Score analysis.

Search Beneish M Score 

 
Refresh
As of 07/26/2021, Long Term Debt to Equity is likely to grow to 0.007743. Also, Debt to Equity Ratio is likely to grow to 0.62. Atea Pharmaceuticals Long Term Debt to Equity is relatively stable at the moment as compared to the past year. Atea Pharmaceuticals reported last year Long Term Debt to Equity of 0.00615. As of 07/26/2021, Accounts Payable Turnover is likely to grow to 51.90, while Receivables Turnover is likely to drop 13.11.
At this time, it appears that Atea Pharmaceuticals is an unlikely manipulator. The earnings manipulation may begin if Atea Pharmaceuticals' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Atea Pharmaceuticals executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Atea Pharmaceuticals' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-4.29
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables
1.0
Asset Quality
N/A
Expense Coverage
1.09
Gross Margin Strengs
0.99
Accruals Factor
1.09
Depreciation Resistance
0.92
Net Sales Growth
0.99
Financial Leverage Condition
N/A

Atea Pharmaceuticals Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Atea Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Revenues43.5 M43.8 M
Slightly Down
Decreasing
Slightly volatile
Selling General and Administrative Expense23.3 M21.6 M
Significantly Up
Increasing
Slightly volatile
Net Cash Flow from Operations320.2 M296.7 M
Significantly Up
Increasing
Slightly volatile
Depreciation Amortization and Accretion20.2 K19 K
Notably Up
Increasing
Slightly volatile
Total Assets931.8 M863.6 M
Significantly Up
Increasing
Slightly volatile
Property Plant and Equipment Net45.6 K48 K
Notably Down
Decreasing
Slightly volatile
Trade and Non Trade Receivables5.2 M5.2 M
Slightly Down
Decreasing
Slightly volatile
Total Liabilities340.8 M315.8 M
Significantly Up
Increasing
Slightly volatile
Current Assets931.6 M863.5 M
Significantly Up
Increasing
Slightly volatile
Assets Non Current149.1 K155 K
Sufficiently Down
Decreasing
Slightly volatile
Current Liabilities340.7 M315.8 M
Significantly Up
Increasing
Slightly volatile
Liabilities Non Current36.9 K36 K
Fairly Up
Decreasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile

Atea Pharmaceuticals Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Atea Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Atea Pharmaceuticals in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Atea Pharmaceuticals' degree of accounting gimmicks and manipulations.

About Atea Pharmaceuticals Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation Amortization and Accretion

20,228.07Share
Atea Pharmaceuticals Depreciation Amortization and Accretion is relatively stable at the moment as compared to the past year. Atea Pharmaceuticals reported last year Depreciation Amortization and Accretion of 19,000

About Atea Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Atea Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Atea Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Atea Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Atea Pharmaceuticals without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Performance Analysis Now

   

Performance Analysis

Check effects of mean-variance optimization against your current asset allocation
All  Next Launch Module

Pair Trading with Atea Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Atea Pharmaceuticals Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Atea Pharmaceuticals and Equillium. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to Atea Pharmaceuticals Piotroski F Score and Atea Pharmaceuticals Altman Z Score analysis. Note that the Atea Pharmaceuticals information on this page should be used as a complementary analysis to other Atea Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Atea Pharmaceuticals Stock analysis

When running Atea Pharmaceuticals price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
The market value of Atea Pharmaceuticals is measured differently than its book value, which is the value of Atea Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Atea Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Atea Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea Pharmaceuticals' market value can be influenced by many factors that don't directly affect Atea Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Atea Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.